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Readily Accessible Substances of Abuse
“Boy, 12, dies after sniffing aerosol.”1 “A bad trip that kills: Abuse of cough remedies
can be lethal.”2 These news headlines highlight a significant problem: abuse of household
products and over-the-counter (OTC) medications. Reasons for abuse of these substances can
vary widely depending on the type of product used. Because these items can be readily found in
pharmacies and stores, it is important for pharmacists to become familiar with the signs and
symptoms of abuse, and street names by which these agents are known (see Table 1).
Pharmacists, especially in the community setting, may be able to identify patterns of abuse since
they are in contact with patients more frequently than other healthcare providers.
Inhalants are the most common type of household products abused. They are substances
which produce chemical vapors or gases that can be intentionally inhaled to cause altered
consciousness or behavior. Inhalants are often generalized into four categories: volatile solvents,
aerosols, gases, and nitrites (see Table 2).
Volatile solvents are liquids that become vapor at room temperature in open containers.
They are found in many products such as paint thinners and removers, gasoline, degreasers,
correction fluid, felt-tip and permanent markers, nail polish and removers, glues and adhesives.
Abuse of typewriter correction fluid by adolescents in the 1980s became widely publicized
through the media. Correction fluid contains the solvents trichloroethylene and 1,1,1trichloroethane.3 Aerosols are sprays that contain propellants and solvents. Toluene, the main
solvent found in aerosols, is the most abused chemical of all inhalants.4 Commonly abused
aerosols products include spray paints, nonstick cooking products, hair and deodorant sprays,
and fabric protectors. Gases are often found in household or commercial propane tanks, butane
lighters, and refrigerants like Freon. Nitrous oxide, also known as laughing gas and “whippets”,

is the most extensively abused gas.5 Although it is a medical anesthetic, nitrous oxide is also
used in whipped cream dispensers and products used to increase performance in racecars. The
fourth category of inhalants is nitrites. Nitrites contain such chemicals as amyl nitrite, cyclohexyl
nitrite, and butyl nitrite. The street names “poppers” or “snappers” refers to illegally distributed
amyl nitrite, which is available by prescription for treatment of angina and cyanide poisoning.
Cyclohexyl nitrite can be found in room deodorizers often used in locker rooms. Nitrites, unlike
other inhalants, are not used primarily for their euphoric effects. Instead, abusers use them to
enhance sexual experiences and performance. Use of nitrites has been related to unsafe sexual
practices and can increase the risk of sexually transmitted infections.6 The effects of nitrites on
the body include vasodilation, tachycardia, sensation of warmth, and facial flushing. Other
consequences associated with nitrite abuse are methemoglobinemia and hemolytic anemia.6
Adolescents who abuse inhalants have been shown to be at risk for higher rates of illegal
drug abuse, school dropout, and co-morbid psychiatric problems.7 Inhalant abuse is prominent in
the adolescent population, but is also seen in adults. In 2001, over 18 million Americans
admitted to using inhalants.8 The National Household Survey on Drugs conducted in 2001,
revealed a wide age distribution of people who have used inhalants: 8.6% of youths aged 12-17,
13.4% of adults aged 18-25, and 7.1% of persons greater than 25 years of age. The number of
new inhalant users in 2001 was reported to be over 1 million, but consisted mainly of persons
below 18 years of age.9 Abuse of inhalants can be deadly and has been associated with over 100
deaths annually.5 The Drug Abuse Warning Network (DAWN) also revealed 1,496 inhalant
related emergency department cases in 2002, a dramatic increase of 187% from the previous
year.10

Self-administration of inhalants is done by various techniques known as “sniffing,”
“snorting,” “spraying,” “huffing”, and “bagging.” 11 Sniffing involves inhaling the vapors from
an open container. Snorting and spraying implies spraying the substance into the nose and
mouth, respectively. “Huffing” refers to the inhalation of vapors from a chemical soaked cloth,
which is either placed over the nose and mouth or directly in the mouth.11 “Bagging” entails
placing the substance of abuse into a bag from which its fumes are inhaled. Inhalation rapidly
supplies a large concentration of these substances to the lungs and brain to produce effects within
minutes.8
The consequences of inhalant abuse differ with short- versus long-term use, and the
substance of abuse. The central nervous system is immediately affected by inhalation of the
chemicals found in solvents, aerosols, and gases. Neurological insult may manifest in a wide
array of physiologic and psychiatric symptoms. Physiologic symptoms include slurred speech,
dizziness, headaches, nausea, vomiting, and lack of coordination. Psychological manifestations
can include visual, auditory, or tactile hallucinations and delusions.12 Chronic abuse of solvents,
gases, and aerosols can affect various organs such as the heart, kidney, lungs, and bone
marrow.13 Physiological dependence following long-term abuse can also lead to withdrawal
symptoms including irritability, tremor, sleep problems, and diaphoresis.12 Abuse during
pregnancy can lead to spontaneous abortion, premature delivery, or birth defects.14 In order to
help decrease intentional inhalation and the dangers associated with their abuse, many products
containing solvents, aerosols and gases have been reformulated or labeled with warnings.15
Inhalant abuse can also be deadly. Among first time abusers of inhalants there is a
mortality rate of approximately 20%.13 Sudden sniffing death syndrome (SSDS) is one of the
most attributable causes of inhalant-related fatalities.14 SSDS is associated most frequently with

aerosols and the gases butane and propane.16 The most common etiology of SSDS is cardiac
arrhythmias. Other causes of deaths linked to inhalant abuse are chemical asphyxiation,
mechanical suffocation (most often seen with “bagging”), and injury associated with impairment
during activities such as driving and operating machinery. 5, 11
Inhalant abuse can be appealing for a variety of reasons. First, they can be easily acquired
from pharmacies and retail stores or already exist in homes and workplaces. Secondly, they are
legal to possess and purchase, with the exception of some substances that require persons to be
18 years or older, such as spray paint. Additionally, their use can be easily concealed. For
example, inhalants can be sprayed or poured onto sleeves, cuffs or shirt collars. Finally, the
euphoria produced is rapid, but also promptly diminishes after approximately 5 to 15 minutes
thereby, reducing the chances of users being caught.8
Like inhalants, some nonprescription drugs, such as cold preparations, stimulants, and
laxatives, are examples of products that are both readily available and potentially abused (see
Table 3). Dextromethorphan, a levorphanol analogue found in varieties of cough and cold
products, has been identified as a drug of abuse among adolescents and young adults.17 In 2002,
52 cases of intentional dextromethorphan abuse were reported to the poison control center in
Michigan within a four and a half month time frame. Among these cases, young males and
females represented approximately two-thirds of cases requiring hospitalization.18
While it is indicated for the symptomatic relief of cough, dextromethorphan has been
used recreationally in large doses to elicit a euphoric phenycyclidine-type “high” and
hallucinogenic effects.19 Oral ingestion of at least 4 ounces of cough syrup, or 240mg of
dextromethorphan, may induce these CNS effects.20 However, in a few cases, doses in excess of
100 times the usual adult dose have not been fatal. 21 Unlike opiates, normal doses of

dextromethorphan have no analgesic, sedative, or respiratory depressant properties.22 However,
massive overdose may cause confusion, excitation, respiratory depression, and toxic psychosis.21
Other symptoms of acute toxicity may include lethargy, ataxia, slurred speech, profuse sweating,
hypertension, nystagmus 23 psychosis and mania.24
Another type of agent found in cold remedies that are commonly abused by teenagers are
antihistamines. Although there are various legitimate uses of antihistamines, recreational use
including hallucinations have been identified.25, 26 Within a 3-year period, the Utah Poison
Control Center identified 80 patients (89% were intentional) from 10 to 18 years of age who had
orally ingested cyclizine.25
In addition to the piperazine H1 antagonist cyclizine, ethanolamines such as
diphenhydramine and dimenhydrinate have also been reported as OTC antihistamines of abuse.26,
27

Doses of dimenhydrinate doses ranging from 8 to 25 tablets, or 400mg to 1250mg, have been

reported to produce intoxication.27, 28 Daily doses as high as 1,600mg of diphenhydramine have
also been reported.28 Other effects include confusion or disorientation, agitation, ataxia, slurred
speech, tremor, anxiety, nervousness, tremor, insomnia, and irritability.25 Antihistamine abuse is
not without consequences, as dependence, tolerance29 and fatalities30 have occurred.
Antihistamine abuse has also been documented in opiate dependents, not only for
inducing hallucinations, but also for potentiating opiate effects. One example is the combination
of pentazocine with the antihistamine tripelennamine known as ‘T’s and Blues.’ This
combination creates a ‘rush’ similar to heroin.31 Similar effects have been reproduced with overthe-counter antihistamines including cyclizine, diphenhydramine, and dimenhydrinate when used
with other opiates. In one study patients used cyclizine, either orally or intravenously, in doses
ranging between 50mg to 800mg to prolong effects of methadone. Acute effects lasted up to 6

hours long when used in combination, as opposed to using cyclizine alone which was estimated
to be 30 to 120 minutes.32
A third cold remedy of concern is pseudoephedrine. Although indicated as a
decongestant, pseudoephedrine has been abused as an anorectic, stimulant, and amphetamine
substitute by dieters, athletes, illegal substance abusers, and truck drivers.33 Pseudoephedrine, an
ephedrine alkaloid, is an indirect-acting sympathomimemetic similar to amphetamine. CNS
stimulatory effects such as euphoria, hyperactivity, insomnia and a feeling of increased energy
have been well documented with amphetamine use, as well as with high doses of ephedrine-like
substances.34 However, even at therapeutic doses of 210mg, pseudoephedrine may induce toxic
effects, including hypertension, tachycardia, arrhythmia, anxiety, psychosis or seizures.35
Serious events have also been documented with pseudoephedrine abuse, such as intracranial
hemorrhage and hypertensive emergency.36, 37
Another concern with pseudoephedrine is its use for the illegal production of
methamphetamines. As a result, the state of California adopted restrictions on the sales of
pseudoephedrine to no more than three packages or no more than nine grams in a single
transaction.38 The FDA has also recently prohibited the sale of dietary supplements containing
ephedrine alkaloids as of April 12, 2004 due to risks of serious adverse events including heart
attack, stroke and death.39 This ban has serious implications on the sales of pseudoephedrine,
since patients may resort to pseudoephedrine as an alternative that may result in a commodity
that is equally harmful.
Caffeine is one of widely used drugs contained in consumer beverages, analgesics and
OTC stimulants. In 2002, there were 2,644 cases of intentional abuse of caffeine reported to the
American Association of Poison Control Centers.40 Some professionals or students who want to

reduce fatigue and stay alert may increase their caffeine intake, however some individuals may
also be resorting to caffeine for abusive purposes. Some patients with eating disorders abuse
caffeine not only for its appetite suppressing, and diuretic properties, but also for physiological
effects such as increased metabolism, increased muscle work output for endurance activities, and
delaying the onset of fatigue resulting from dieting.41-43 Furthermore, caffeine has also been
known to be abused athletes in attempt to improve athletic performance, alter body composition,
and increase levels of energy.44
Prolonged caffeine consumption can result in dependence, increased tolerance, and
produce withdrawal symptoms, and death.45, 46 In addition, excessive caffeine consumption may
result in caffeine toxicity, or caffeinism. Caffeinism, defined as a single ingestation of caffeine
doses greater than 250mg can produce symptoms mimicking anxiety, including nervousness,
restlessness, insomnia, excitement, muscle twitching, gastrointestinal disturbances, rambling
flow of thought and speech, agitation, and inexhaustibility.47 In addition, arrhythmias,
hypokalemia, hyperglycemia, myocardial infarction and death may result.41-43 The minimum
lethal dose for humans is estimated at 150-200 mg/kg.48 In one case report, a 19-year old female
had died after ingesting an estimate of 18 grams of caffeine from an over-the-counter appetite
suppressant. 49
Abuse of other products have also been identified in dieters and patients with eating
disorders, such as anorexia or bulemia. In 2003, nationwide, 6% of high school students had
vomited or taken a laxative to keep from gaining weight. The prevalence of this occurrence was
higher among female students, comprising of 8.4%, than 3.7 % of male students.50 These
individuals may seek over-the-counter products, such as laxatives or ipecac, for weight control.
Eating disorders are often associated with devasting and medical and psychological

consequences. Signs and symptoms of eating disorders include fatigue, dizziness, or lack of
energy, amenorrhea, sore throat, gastroesophageal reflux disease, abdominal pain, cold
intolerance, constipation, polyuria, polydipsia, and palpitations.51, 52 Complications include
growth retardation,53 loss of dental enamel with chronic vomiting,54 pubertal delay or arrest,55
predisposition to osteoporosis and increased risk fracture.56
Chronic use of laxatives for facilitating the passage and elimination of feces is often
associated with the elderly, however, some adolescents, college students, and young adults,
especially women, may use laxatives for weight control.57 In 2002, the American Association of
Poison Control Centers reported 880 cases of intentional abuse of laxatives.40 Stimulant
laxatives, such as senna, and bisacodyl, appear to be the most commonly abused agents
compared to other laxative types, such as bulk, osmotic, surfactant and emollient laxatives.58
Stimulant laxatives may be the preferred agents because these agents facilitate rapid high volume
of fecal discharge, which patients may perceive as caloric intake that has been successfully
nullified prior to the intestinal absorption process;59, 60 however, caloric absorption is actually
reduced only minimally by approximately 12%.61
Chronic and excessive laxative abuse may cause diarrhea that alternates with
constipation, nausea, abdominal pain, and other gastrointestinal symptoms. Loss of stool fluid
and electrolytes, such as sodium, potassium and magnesium, may lead to dehydration and acidbase disturbances. Secondary complications may also result including lethargy, polydipsia,
muscle weakness, worsening of constipation, renal damage, cardiac arrhythmias and increased
risk of sudden death.62
Ipecac is another nonprescription agent that is abused in some patients with eating
disorders. It is indicated as an emetic for use in some poisonings, however, patients with eating

disorders use it inappropriately to remove food from the stomach for weight control. Chronic
administration of ipecac may result in GI effects, such as grossly bloody stools, muscle
weakness, and cardiomyopathy.63 Several case reports have documented hospitalizations and
deaths associated with ipecac abuse. Acute lethal doses for adults have been identified to be as
low as 600-1200mg.64 In one fatal case, a 26-year-old bulimic woman had been drinking three to
four bottles of syrup of ipecac per day after meals to lose weight over a three-month period.65
In conclusion, the abuse of over-the-counter products, such as household products and
nonprescription drugs, is often overlooked. Abuse with these products may be more appealing
than illicit drug use for several reasons, such as being legal to possess and purchase, highly
accessible, and relatively low in cost. Since these products are readily available in the home or
for purchase at a retail store, patients perceive their use as safe. Thus, community pharmacists
can play a very important role in educating the public about the dangers of household products,
and the safe and appropriate use of OTC products. Finally, pharmacists should be cautious in
supplying large quantities of nonprescription agents that may have abuse potential.

Table 1: Street Names Associated with Products of Abuse
AGENT ABUSED
STREET TERMS
Dextromethorphan

Volatile Solvents
Aerosols
Gases
Nitrites

Skittles, Triple C’s (C-CC), Robo, Robo-tripping,
Red Devils, DXM, Tussin,
Dex
Gluey
Glading
Toncho, Head cleaner,
Whippets
Snappers, Poppers Rush,
Climax, Amys, Pearls, Bolt

ASSOCIATED
PRODUCTS
Coricidin®, Coricidin HBP
Cough & Cold® ,
Robitussin DM®
Model glue, rubber cement
Air fresheners
Octane booster, video
cleaner
Butyl nitrite, Amyl nitrite,
Isobutyl nitrite, Locker
room deodorizers

Table 2: Description of Common Household Products of Abuse
Nonprescription Desired Abuse Potential Overdose
Example of
agent
Effects
Effects
Products
Volatile Solvents
Euphoria,
Peripheral
Liquid Paper,
(Example of
intoxication,
neurophathy, hepatic
Wite-Out,
Chemicals:
hallucination
and renal toxicity,
Marks-A-Lot
toluene, benzene,
bone marrow
markers, Rubber
trichloroethylene,
suppression
Cement, paint
acetone, hexane)
neurotoxic effects,
thinners and
cardiac arrhythmias,
removers, nail
asphyxiation
polish and
remover
Aerosols
Euphoria,
Hepatotoxicity,
Spray paints,
(Example of
intoxication,
asphyxiation, cardiac deodorant sprays,
chemicals:
hallucination
arrhythmias, hearing
hair sprays,
toluene, dimethyl
loss
nonstick cooking
ether,
sprays, fabric
fluorocarbon,
protector spays,
butane, propane,
air fresheners
Freon)
Gases
Euphoria,
Hypotension,
Laughing gas,
(Example of
intoxication,
neurotoxic effects,
Freon, Lighter
chemicals:
hallucination
peripheral neuropathy, fluid, propane
Butane, propane,
limb spasms, cardiac
tanks, whipped
nitrous oxide)
arrhythmias
cream dispensers
Nitrites
Enhance sexual Orthostatic
Locker Room,
(Example of
performance
hypotension,
Climax, Rush,
chemicals: amyl
and experience tachycardia,
nitrite, cyclohexyl
immunosuppression
ntrite, butyl
nitrite)

Table 3: Description of OTC products of abuse
Nonprescription
agent

Potential Overdose
Effects

Example of
Products

Dextromethorphan Euphoria,
hallucination

Confusion, excitation,
nervousness,
hypertension,
respiratory
depression,
psychosis, mania

Antihistamines
(ex: cyclizine,
dimenhydrinate,
diphenhydramine)

Hallucination,
euphoria,
potentiation of
opiates

Pseudoephedrine

Stimulant,
anorectic,
euphoria,
illegal
manufacturing
of
methamphetam
ines
Stimulant,
anorectic

Confusion,
disorientation,
hallucinations,
agitation, tremor,
insomnia, irritability
Hypertension,
tachycardia,
arrhythmia, anxiety,
psychosis, seizures,
insomnia

Robitussin-DM,
Tylenol Cough,
Vicks NyQuil,
Coricidin,
Coricidin HBP
Cough & Cold
Benadryl,
Dramamine,
Marezine

Caffeine

Desired Abuse
Effects

Laxatives

Weight loss

Ipecac

Weight loss

Insomnia, anxiety,
nervousness,
restlessness,
headache, excitement,
muscle twitching,
tachycardia,
psychomotor agitation
Weakness, muscle
cramps, sweating,
arrhythmia, renal
damage, dehydration,
acid-base
disturbances, nausea,
vomiting, diarrhea,
abdominal cramping
Diarrhea, grossly
bloody stools, muscle
weakness,
bradycardia,
cardiomyopathy

Sudafed
Tablets,
Dimetapp
Decongestant
Non-Drowsy
Liqui-Gels

Vivarin,
NoDoz,
Enerjets

Metamucil,
Dulcolax,
Fleet, Colace

Ipecac syrup
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